Monthly Archives: August 2016

Pharmaceutical pricing got thrown onto the front page again last week, causing the expected anaphylactic reactions among politicians, practitioners, and parents. The root of this crisis: Epipen’s 600% price increase over the past eight years. The biannual upticks underlying that

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Sail-away It’s January on a ship in the South Pacific. Instead of enjoying hula and coconuts, I’m struggling to

This post was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Those of us in biotech tend to focus our attention on drug discovery and development, but it is also

This post was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. When I was a graduate student, I listened to the famous developmental biologist Lewis Wolpert say, “It is not birth

Biotech has been one of the hottest sectors in the venture capital asset class over the past few years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has